Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?Fernando Bessone|World Journal of Gastroenterology|2010Cited by 252
The present and future disease burden of hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infections with today's treatment paradigm – volume 2Angelos Hatzakis, E. Nurmukhametova, Vladimir Chulanov et al.|Journal of Viral Hepatitis|2015Cited by 125
Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2V A Saraswat, N. Mamonova, Suzanne Norris et al.|Journal of Viral Hepatitis|2015Cited by 93
Strategies to manage hepatitis <scp>C</scp> virus (<scp>HCV</scp>) infection disease burden – volume 2Edward Gane, E. Nurmukhametova, David Kershenobich et al.|Journal of Viral Hepatitis|2015Cited by 54
60 SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTIONMark Sulkowski, Gerhard Steinmann, Fernando Bessone et al.|Journal of Hepatology|2011Cited by 39